Cogent Biosciences, Inc. COGT
At closeNov 6, 2026, 4:00 PM EST
After hours · Nov 6, 4:00 PM ET
- YTD
- -10.91%
- 1 year
- +114.98%
- Market cap
- 5.49B
- EPS (ttm)
- -2.16
- Shares out
- 173.52M
- Forward P/E
- -26.45
- YTD return
- -10.91%
- 1-year return
- +114.98%
- Volume
- 1.48M
- Avg volume
- 2.00M
- Open
- 29.53
- Previous close
- 29.58
- Day's range
- 28.97 – 31.69
- 52-week range
- 14.72 – 42.84
- Analysts
- Strong Buy
- Price target
- 55.82 (+76.4%)
- Earnings date
- Nov 9, 2026
5D +0.25 (+0.80%)
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 9.32
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 0.00%
- Short % of float
- 11.39%
- 50-day average
- 31.93
- 200-day average
- 35.52
Analyst view
Consensus: strong buy
- Target (low)
- 45.00
- Target (mean)
- 55.82
- Target (high)
- 62.00
- Strong buy2
- Buy9
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 9, 2026
Expected Nov 9, 2026. Consensus EPS estimate -0.57946.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 9, 2026 | Sep 30, 2026 | -0.55726 | — | — | — |
| Aug 10, 2026 | Jun 30, 2026 | -0.55497 | -0.52 | +0.03 | +6.30% |
| May 5, 2026 | Mar 31, 2026 | -0.53 | -0.53 | 0.00 | 0.00% |
| Feb 17, 2026 | Dec 31, 2025 | -0.51 | -0.55 | -0.04 | -7.84% |
| Nov 7, 2025 | Sep 30, 2025 | -0.54 | -0.50 | +0.04 | +7.41% |
| Aug 5, 2025 | Jun 30, 2025 | -0.55 | -0.53 | +0.02 | +3.64% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 16, 2026 | Wedbush | reit | Outperform | Outperform |
| Sep 15, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 17, 2026 | Piper Sandler | main | Overweight | Overweight |
| Aug 12, 2026 | Guggenheim | main | Buy | Buy |
| May 29, 2026 | Wedbush | reit | Outperform | Outperform |
| May 6, 2026 | HC Wainwright & Co. | main | Buy | Buy |
About Cogent Biosciences, Inc.
Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma; CGT4255, a novel ErbB2 mutant program, which is focused on actionable and underserved mutations in a solid tumor systemic and CNS involved indications; and CGT6297, a Novel PI3Ka mutant-selective inhibitor. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- cogentbio.com
News
If You Invested $1000 In Cogent Biosciences Stock 5 Years Ago, You Would Have This Much Today - Here’s How Much You Would Have Made Owning Cogent Biosciences Stock In The Last 5 Years
$1000 Invested In Cogent Biosciences 5 Years Ago Would Be Worth This Much Today - Here’s How Much You Would Have Made Owning Cogent Biosciences Stock In The Last 5 Years
Wedbush Reiterates Outperform on Cogent Biosciences, Maintains $55 Price Target 
HC Wainwright & Co. Reiterates Buy on Cogent Biosciences, Maintains $55 Price Target 
FDA Accepts Cogent Biosciences' NDA For Bezuclastinib In Patients With Advanced Systemic Mastocytosis 
Cogent Biosciences Enters Commercial Supply Agreement With Hovione On Sept 1, 2026; To Purchase Minimum Percentages Of Bezuclastinib Products From Hovione; Agreement Effective For Five-Year Term With Automatic Two-Year Renewals - $100 Invested In Cogent Biosciences 5 Years Ago Would Be Worth This Much Today
Piper Sandler Maintains Overweight on Cogent Biosciences, Raises Price Target to $55
Your note
Sign in to keep a note on COGT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| FAIRMOUNT FUNDS MANAGEMENT LLC | Director | Sale | Jan 21, 2026 | 0 |
| GREEN JOHN L | Chief Financial Officer | Sale | Dec 25, 2025 | 131,834 |
| KEARNS EVAN D J.D. | Officer | Sale | Dec 25, 2025 | 109,398 |
| MORRIS ARLENE M. | Director | Sale | Aug 26, 2026 | 0 |
| PINNOW COLE | Officer | Stock Award(Grant) | Dec 16, 2025 | 216,650 |
| ROBBINS ANDREW R. | Chief Executive Officer | Stock Gift | May 18, 2026 | 657,503 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 14.80% | 25,681,174 | 812.68M | Jun 29, 2026 |
| Blackrock Inc. | 10.00% | 17,352,646 | 549.12M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 4.65% | 8,072,411 | 255.45M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.27% | 7,412,330 | 234.56M | Jun 29, 2026 |
| State Street Corporation | 4.01% | 6,964,919 | 220.40M | Jun 29, 2026 |
| Jupiter Topco LLC | 3.82% | 6,624,848 | 209.64M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.97% | 5,156,952 | 163.19M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.49% | 4,316,858 | 136.61M | Sep 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.25% | 3,900,938 | 123.45M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.15% | 3,724,033 | 117.85M | Jun 29, 2026 |
| Fidelity Securities Fund-Fidelity Small Cap Growth Fund | 1.45% | 2,509,157 | 79.40M | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Value Index Fund | 1.36% | 2,358,212 | 74.63M | Jun 29, 2026 |